International cohort studies suggest that adding azithromycin to hydroxychloroquine (HCQ) treatment may increase heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length of ECG. Severe adverse events associated with HCQ-azithromycin were compared to HCQ-amoxicillin in rheumatoid arthritis patients aged 18+ and followed up over 30 days. A total of 323,122 and 351,956 users of HCQ-azithromycin and HCQ-amoxicillin were included. When azithromycin was added to HCQ, an increased risk of 30-day cardiovascular mortality (HR2.19), chest pain/angina (HR 1.15), and heart failure (HR 1.22) were observed. HCQ is a drug for malarial and for systemic lupus erythematosus. It recently received Emergency Use Authorization by the FDA for use to treat COVID-19 patients. Source: https://www.medrxiv.org/
A circadian subtype of depression is associated with earlier disease onset, more severe clinical features,…
A longitudinal study of 995 U.S. older adults found that frequent and unintentional daytime napping…
A multicohort genetic association study found that the ancestry-enriched CD36 Y325* variant accounted for a…
An American College of Cardiology scientific statement emphasizes that exercise should be prescribed as a…
A 16-week low-fat vegan diet was associated with significant reductions in body weight, visceral fat,…
A systematic review and meta-analysis of 27 studies involving 88,830 participants found that intensive blood…
This website uses cookies.